Axsome Therapeutics Analysts Increase Their Forecasts Following Q2 Results
Axsome Therapeutics (NASDAQ:AXSM) reported Q2 losses of 99 cents per share and sales of $218.4 million, missing analyst estimates. Analysts have mixed price targets for the stock.
Axsome made less money than experts thought it would, but some analysts still think the company might do better going forward. When experts change their minds about a company's future, it's worth paying attention to see if the company is actually improving.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.